Natera Inc Stock Price, News & Analysis

Natera (NASDAQ: NTRA), a leader in cell-free DNA testing and precision medicine, has achieved a significant milestone with over 300 peer-reviewed publications featuring its technology. The publications span prestigious journals including Nature, Nature Medicine, and others, demonstrating the company's scientific leadership.

The milestone encompasses 150+ oncology publications (140+ focused on Signatera™), 100+ publications on Women's Health technologies, and 60+ publications on Organ Health solutions. These studies validate Natera's contributions to disease detection and clinical decision-making across multiple medical disciplines.

Natera (NASDAQ: NTRA) has launched its proprietary AI foundation model platform aimed at advancing diagnostic and therapeutic innovation in precision medicine. The platform is built on one of the largest multimodal oncology datasets, including over 250,000 tumor exomes and 1 million+ plasma timepoints.

The platform consists of three integrated layers: a data foundation layer with extensive oncology datasets, a core model layer powered by over 1 billion parameters, and an application layer featuring tools like the Digital Patient Simulator, Real-Time Trial Matching, and NeoPredict. Initial pilot programs have demonstrated strong performance in recommending immunotherapy and predicting treatment responses.

Natera (NASDAQ: NTRA) has announced positive topline results from the Phase III IMvigor011 trial in muscle-invasive bladder cancer (MIBC), utilizing their Signatera ctDNA test. The trial demonstrated that Signatera-positive patients treated with atezolizumab showed significant improvements in disease-free survival and overall survival.

The study enrolled approximately 760 patients who underwent Signatera testing post-surgery. Notably, patients who remained Signatera-negative showed exceptional outcomes, with 100% overall survival at 12 months and 98% at 18 months. Disease-free survival rates were 92% at 12 months and 88% at 18 months after surgery.

Following these results, Natera will finalize its premarket approval application to the FDA for Signatera as a companion diagnostic for atezolizumab treatment selection in MIBC patients post-cystectomy.

Natera (NASDAQ: NTRA) reported strong Q2 2025 financial results with total revenues of $546.6 million, up 32.2% year-over-year. The company achieved significant milestones including a gross margin of 63.4% and processed 853,100 tests, a 12.2% increase from Q2 2024.

Notable highlights include 50.6% growth in oncology tests to 188,800 units and positive cash flow of $24.3 million. The company raised its 2025 revenue guidance to $2.02-$2.10 billion, an $80 million increase at the midpoint. However, Natera reported a net loss of $100.9 million ($0.74 per share), impacted by legal accruals and stock-based compensation expenses.

Natera (NASDAQ: NTRA) has launched Fetal Focus, a groundbreaking noninvasive prenatal test (NIPT) for inherited conditions. The test addresses a critical gap in prenatal care by screening fetuses directly for five commonly tested genes when the biological father is unavailable for testing.

The launch is backed by initial data from the EXPAND clinical trial, which has enrolled approximately 1,300 participants. In its first milestone readout (n=101), Fetal Focus demonstrated 91% sensitivity and successfully identified all 5 cases of homozygous variants. The test utilizes Natera's proprietary LinkedSNP™ technology and is validated for analyzing genes associated with cystic fibrosis, spinal muscular atrophy, alpha-thalassemia, and beta-hemoglobinopathies including sickle cell disease.

Natera (NASDAQ: NTRA) announced its significant presence at the 2025 World Transplant Congress (WTC) with 16 abstracts, including five oral presentations, showcasing comprehensive data on its Prospera™ test across kidney, heart, and lung transplantation. The presentations highlight results from the Trifecta series of studies and include data from recently published studies in the American Journal of Transplantation, such as the PEDAL clinical trial for kidney transplants and Prospera Heart's performance with Donor Quantity Score (DQS).

Key presentations feature Prospera Kidney's utility in monitoring treatment of chronic antibody-mediated rejection and various studies demonstrating the test's effectiveness across different transplant types. The congress, taking place August 2-6 in San Francisco, represents one of the most extensive collections of data on Natera's Prospera test to date.

Natera (NASDAQ: NTRA), a leader in cell-free DNA and precision medicine, has scheduled its Q2 2025 earnings release for August 7, 2025, after market close. The company will host a conference call and webcast at 1:30 PM PT (4:30 PM ET) to discuss the results.

Investors can join via phone using dial-in numbers 1-888-770-7321 (Domestic) or 1-929-201-7107 (International) with Conference ID 7684785. A webcast will be available at https://events.q4inc.com/attendee/169947359, with a replay accessible on Natera's investor relations website.

Natera (NASDAQ: NTRA) has launched the TEODOR trial, a Phase II randomized controlled trial studying the use of Signatera™ in early-stage breast cancer treatment. The trial aims to identify hormone receptor-positive (HR+), HER2-negative breast cancer patients who could safely avoid chemotherapy before surgery.

The study, sponsored by the Austrian Breast & Colorectal Cancer Study Group (ABCSG), will enroll approximately 250 patients across 15 Austrian sites. Patients who test Signatera-negative and show favorable endocrine sensitivity will be randomized to receive either endocrine therapy or chemotherapy. The trial's primary endpoint focuses on neoadjuvant therapy response, with secondary endpoints including breast cancer recurrence and overall survival.

Natera (NASDAQ: NTRA) announced the publication of its PEDAL study results in the American Journal of Transplantation, demonstrating the prognostic capabilities of its Prospera™ kidney transplant monitoring test. The study, involving 488 kidney transplant recipients across 28 centers, focused on donor-derived cell-free DNA (dd-cfDNA) trends following rejection.

The groundbreaking results showed that patients with low/decreasing Prospera trends had 60x higher odds of positive outcomes after one year and were 13x more likely to have resolving kidney dysfunction. Notably, 97.5% of cases with sustained elevated Prospera trends experienced negative clinical outcomes, highlighting the test's effectiveness in post-rejection risk assessment.